Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiogenesis Starts Clinical Trial For Its Pearl Robotic TMR System

This article was originally published in The Gray Sheet

Executive Summary

Cardiogenesis is developing a minimally-invasive transmyocardial revascularization (TMR) procedure for use on its Pearl 5.0 robotic laser delivery system, which is expected to receive FDA clearance within a few months

You may also be interested in...



People In Brief

Shakeup at FoxHollow: Ron Steckel replaces David Martin as COO, and Richard Zimmer replaces Bill Hoffman as VP-sales. Steckel moves up from senior VP-operations and research & development, where he focused on improving operating efficiency. Zimmer has spent two years with FoxHollow, serving as director of sales since October. The firm recently announced plans for new studies of its SilverHawk plaque excision system (1"The Gray Sheet" Jan. 16, 2006, p. 7). However, FoxHollow's stock has dropped 38.5% from $45.46 on Dec. 12, when the firm announced the resignation of CEO Robert Thomas, to close Feb. 10 at $27.95 (2"The Gray Sheet" Jan. 9, 2006, p. 13)...

People In Brief

Shakeup at FoxHollow: Ron Steckel replaces David Martin as COO, and Richard Zimmer replaces Bill Hoffman as VP-sales. Steckel moves up from senior VP-operations and research & development, where he focused on improving operating efficiency. Zimmer has spent two years with FoxHollow, serving as director of sales since October. The firm recently announced plans for new studies of its SilverHawk plaque excision system (1"The Gray Sheet" Jan. 16, 2006, p. 7). However, FoxHollow's stock has dropped 38.5% from $45.46 on Dec. 12, when the firm announced the resignation of CEO Robert Thomas, to close Feb. 10 at $27.95 (2"The Gray Sheet" Jan. 9, 2006, p. 13)...

CardioGenesis’ PMR On Deck For FDA Dispute Resolution Panel Review

CardioGenesis is retaining Covington & Burling to help prepare for its upcoming dispute resolution panel. The regulatory law firm consulted Lifecore Biomedical in the only other MDDRP review

Related Content

UsernamePublicRestriction

Register

MT022513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel